- Home
- AGIO vs BCAT Comparison
AGIO vs BCAT Comparison
Compare AGIO & BCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- BCAT
- Stock Information
- Founded
- AGIO 2007
- BCAT 2020
- Country
- AGIO United States
- BCAT United States
- Employees
- AGIO N/A
- BCAT N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- BCAT Finance/Investors Services
- Sector
- AGIO Health Care
- BCAT Finance
- Exchange
- AGIO Nasdaq
- BCAT Nasdaq
- Market Cap
- AGIO 2.0B
- BCAT 1.7B
- IPO Year
- AGIO 2013
- BCAT N/A
- Fundamental
- Price
- AGIO $33.23
- BCAT $15.66
- Analyst Decision
- AGIO Buy
- BCAT
- Analyst Count
- AGIO 7
- BCAT 0
- Target Price
- AGIO $56.33
- BCAT N/A
- AVG Volume (30 Days)
- AGIO 975.9K
- BCAT 308.8K
- Earning Date
- AGIO 02-13-2025
- BCAT 01-01-0001
- Dividend Yield
- AGIO N/A
- BCAT 9.38%
- EPS Growth
- AGIO N/A
- BCAT N/A
- EPS
- AGIO 11.80
- BCAT 1.43
- Revenue
- AGIO $32,871,000.00
- BCAT N/A
- Revenue This Year
- AGIO $33.41
- BCAT N/A
- Revenue Next Year
- AGIO $172.14
- BCAT N/A
- P/E Ratio
- AGIO $2.78
- BCAT $11.41
- Revenue Growth
- AGIO 36.79
- BCAT N/A
- 52 Week Low
- AGIO $21.18
- BCAT $13.67
- 52 Week High
- AGIO $62.58
- BCAT $16.38
- Technical
- Relative Strength Index (RSI)
- AGIO 36.88
- BCAT 51.42
- Support Level
- AGIO $31.39
- BCAT $15.40
- Resistance Level
- AGIO $35.03
- BCAT $15.81
- Average True Range (ATR)
- AGIO 1.71
- BCAT 0.21
- MACD
- AGIO 0.54
- BCAT 0.06
- Stochastic Oscillator
- AGIO 39.91
- BCAT 80.26
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
About BCAT BlackRock Capital Allocation Term Trust of Beneficial Interest
BlackRock Capital Allocation Trust is a non-diversified, closed-end management investment company. The investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation.